ATyr Pharma Plans Investigational New Drug Filing for ATYR0101 in Pulmonary Fibrosis

MT Newswires Live

2025/05/14

ATyr Pharma (ATYR) said Wednesday it has advanced ATYR0101 to the investigational new drug candidate stage to potentially treat pulmonary fibrosis.

Chief Executive Sanjay S. Shukla said they anticipate filing an IND application in H2 of 2026.

The company said preclinical data showed ATYR0101 can induce cell death of myofibroblasts through interaction with LTBP-1. Myofibroblasts are the cells that drive progression of fibrosis.

Shares of the company were down 1.2% in early trading Wednesday.

Price: 3.27, Change: -0.04, Percent Change: -1.21

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535762020"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535762020\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535762020?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535762020","market":"sg","top_or_hot":-1,"title":"ATyr Pharma Plans Investigational New Drug Filing for ATYR0101 in Pulmonary Fibrosis","media":"MT Newswires Live","content":"<html><body><p> ATyr Pharma (ATYR) said Wednesday it has advanced ATYR0101 to the investigational new drug candidate stage to potentially treat pulmonary fibrosis.</p><p>Chief Executive Sanjay S. Shukla said they anticipate filing an IND application in H2 of 2026.</p><p>The company said preclinical data showed ATYR0101 can induce cell death of myofibroblasts through interaction with LTBP-1. Myofibroblasts are the cells that drive progression of fibrosis.</p><p>Shares of the company were down 1.2% in early trading Wednesday.</p><p>Price: 3.27, Change: -0.04, Percent Change: -1.21</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ATyr Pharma Plans Investigational New Drug Filing for ATYR0101 in Pulmonary Fibrosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nATyr Pharma Plans Investigational New Drug Filing for ATYR0101 in Pulmonary Fibrosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-14 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ATyr Pharma (ATYR) said Wednesday it has advanced ATYR0101 to the investigational new drug candidate stage to potentially treat pulmonary fibrosis.</p><p>Chief Executive Sanjay S. Shukla said they anticipate filing an IND application in H2 of 2026.</p><p>The company said preclinical data showed ATYR0101 can induce cell death of myofibroblasts through interaction with LTBP-1. Myofibroblasts are the cells that drive progression of fibrosis.</p><p>Shares of the company were down 1.2% in early trading Wednesday.</p><p>Price: 3.27, Change: -0.04, Percent Change: -1.21</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATYR","symbol_name":"ATYR PHARMA INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535762020","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535762020","pubTimestamp":1747230473,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ATyr Pharma  said Wednesday it has advanced ATYR0101 to the investigational new drug candidate stage to potentially treat pulmonary fibrosis.Chief Executive Sanjay S. Shukla said they anticipate filing an IND application in H2 of 2026.The company said preclinical data showed ATYR0101 can induce cell death of myofibroblasts through interaction with LTBP-1. Myofibroblasts are the cells that drive progression of fibrosis.Shares of the company were down 1.2% in early trading Wednesday.Price: 3.27, Change: -0.04, Percent Change: -1.21","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATYR":"ATYR PHARMA INC","BK4139":"生物科技"},"translate_title":"ATyr Pharma计划提交ATYR0101治疗肺纤维化的研究性新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATYR":0.9},"content_text":"ATyr Pharma (ATYR) said Wednesday it has advanced ATYR0101 to the investigational new drug candidate stage to potentially treat pulmonary fibrosis.Chief Executive Sanjay S. Shukla said they anticipate filing an IND application in H2 of 2026.The company said preclinical data showed ATYR0101 can induce cell death of myofibroblasts through interaction with LTBP-1. Myofibroblasts are the cells that drive progression of fibrosis.Shares of the company were down 1.2% in early trading Wednesday.Price: 3.27, Change: -0.04, Percent Change: -1.21","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}